Big Pharma in the Cancer Spotlight?
Biotech investors are unusually quiet for this time of year. Over the past few years the biotech sector has dominated the news coming out of the annual American Society of Clinical Oncology (ASCO) meeting, the world's most important cancer conference. And their stocks typically start moving a week or two ahead of the meeting in anticipation of those headlines.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.